COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.
The G7 has committed one billion doses since the February 2021 virtual G7 Early Leaders’ Summit, including pledges made at the G20 Global Health Summit hosted by Prime Minister Draghi and President von der Leyen and the Gavi COVAX AMC Summit hosted by Prime Minister Yoshihide Suga of Japan.
COVAX partners applaud G7 leaders’ support for global public health.
8444
全球获取机制合作伙伴称赞七国集团领导人对全球公共卫生的支持。
In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.
Building on the momentum of the G20 Global Health Summit hosted by Prime Minister Draghi and President von der Leyen and the Gavi COVAX AMC Summit hosted by Prime Minister Yoshihide Suga of Japan, G7 countries committed to share at least 870 million doses of COVID-19 vaccines directly, with the aim to deliver at least half by the end of 2021, and reaffirmed their support for COVAX as “the primary route for providing vaccines to the poorest countries.”
8446
全球获取机制的合作伙伴欢迎这一承诺，也欢迎各国继续支持大规模出口、促进自愿许可和非营利性全球生产。
COVAX partners welcome this commitment, along with continued support for exporting in significant proportions, promotion of voluntary licensing and not-for-profit global production.
8447
全球获取机制期待尽快看到疫苗流向各国。
COVAX looks forward to seeing doses flowing to countries as soon as possible.
Facing an urgent supply gap, COVAX is focused on securing as many shared doses as possible immediately, as the third quarter of this year is when the gap between deliveries and countries’ ability to absorb doses will be greatest.
8449
全球获取机制将与七国集团和其他国家合作，尽可能快速、公平地分配疫苗。
COVAX will work with the G7 and other countries that have stepped up to share doses as rapidly and equitably as possible.
This will help address short-term supply constraints currently impacting the global response to COVID-19 and minimize the prospect of future deadly variants.